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Objetivo: Los parches de mucoadherente bucal fueron desarrollados y evaluados por la 
administración sistémica de la pioglitazona en la cavidad oral. Pioglitazona pertenece a una clase 
nueva de medicamentos antidiabéticos orales conocida como tiazolidindionas.
Material y Método: los parches mucoadherente bucal de pioglitazona fue formulado con Eudragit 
RS100 y HPMC K4M (polímero mucoadherentes) y fueron elaboradas por el método de fundición 
solvente. Se evaluaron diferentes formulaciones de parches mediante parámetros físicos como 
uniformidad de espesor, índice de hinchazón, pH de la superficie, uniformidad de peso, resistencia 
al plegado, fuerza mucoadherentes y parámetros in vitro como uniformidad de contenido del 
fármaco y estudios de liberación y estudios ex vivo del tiempo de mucoadhesión del fármaco.
Resultados: Los resultados obtenidos para los parámetros estudiados fueron: uniformidad de 
espesor, 0.27±0.45 mm; uniformidad de peso, 40.81±0.66 mg; pH superficial, 6.5; resistencia al 
plegado, > 300. Los ensayos in vitro dieron los siguientes resultados: uniformidad de contenido 
del fármaco, 98.58±2.05%; índice de hinchazón, 131±0.79%; fuerza mucoadherente, 38.20±1.75; y 
tiempo de liberación del farmaco (95.18±1.98%) y el ensayo ex vivo del tiempo de mucoadhesión del 
fármaco fue de 4±1.26 h.  Los datos también se ajustaron a distintos modelos cinéticos para ilustrar 
su difusión anómala (no Fickian).
Conclusiones: El resultado reveló que los parches bucales de pioglitazona fue el modo más 
adecuado de fármacos de acción terapéutica prometedora. Los Parches bucales de pioglitazona 
pueden resultar una potencial forma de dosificación farmacéutica para sostener la liberación del 
fármaco y reducir la frecuencia de la dosis.
PALABRAS CLAVE: Eudragit, HPMC K4M, Método de fundición solvente de Mucoadhesion.
ABSTRACT
Aim: The mucoadhesive buccal patches were developed and evaluated for systemic administration 
of Pioglitazone in the oral cavity. Pioglitazone belongs to a novel class of oral antidiabetic drugs 
known as Thiazolidinediones.
Materials and Methods: The mucoadhesive buccal patches of Pioglitazone was formulated using 
Eudragit RS100 and HPMC K4M (mucoadhesive polymer) and were prepared by solvent casting 
method. Different patch formulations were evaluated for its physical parameters like thickness 
uniformity, swelling index, surface pH, uniformity of weight, folding endurance, mucoadhesive 
strength and in vitro parameters like drug content uniformity and drug release studies, and ex vivo 
parameters like mucoadhesion time. 
Results: Data for the parameters was found to be: thickness uniformity (0.27±0.45mm); uniformity 
of weight (40.81±0.66 mg), surface pH (6.5), folding endurance (>300), drug content uniformity 
(98.58±2.05%), swelling index (131±0.79%), mucoadhesive strength (38.20±1.75), in vitro drug release 
studies (95.18±1.98%) and ex vivo mucoadhesion, time of optimized formulation (4±1.26 h).  The data 
was also fitted to different kinetic models to illustrate its anomalous (non-fickian) diffusion.
Conclusions: The result revealed that Pioglitazone loaded buccal patches was most suitable mode 
of drug delivery for promising therapeutic action. Buccal patches of Pioglitazone can prove to 
be potential pharmaceutical dosage form for sustaining the drug release and reducing the dose 
frequency.
KEY WORDS: Eudragit, HPMC K4M, Mucoadhesion, Solvent casting method.
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Table 1. Formulation Table of Pioglitazone Loaded 
Mucoadhesive Buccal Patches.
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INTRODUCTION
In recent years, there has been outstanding interest in the 
buccal drug delivery of active medicaments, particularly 
in overcoming deficiencies associated with conventional 
oral drug delivery system. Problems such as extensive 
hepatic first-pass metabolism and drug degradation in 
the gastrointestinal environment can be prevented by 
administering the drug via the buccal route of oral cavity1. 
Moreover, there are enormous advantages of buccal drug 
delivery like increased bioavailability due to by-pass of first 
pass metabolism, improved patient compliance due to the 
elimination of associated pain with injections and sustained 
release for prolonged duration of time. Large contact surface 
area of buccal region contributes to rapid and extensive 
drug absorption and can be used in case of unconscious 
and less cooperative patients2,3. Buccal patches are a novel 
form of mucoahesive systems, which are thin, flexible, 
elastic and soft and usually prepared by mild bioadesive 
and biodegradable polymers4. Mucoadhesion is known to 
increase the intimacy and duration of contact between drug- 
containing polymer and a mucous surface5. Type II diabetes 
mellitus is a chronic illness with progressively leading to 
micro and macrovascular complications. Pathophysiology 
of diabetes mellitus is related with development of insulin 
resistance in target tissues, increased hepatic glucose 
production and ultimately failure of insulin secretion by 
pancreatic β-cell. These pathologies lead to hyperglycemia 
and hyperinsulinism6. Pioglitozone is chemically (RS)-
5-(4-[2-(5-ethylpyridin-2-yl) ethoxbenzylthiazolidine-2, 
4-dione and is an anti-diabetic drug which is used in the 
treatment of type II diabetes7. It is a potent and highly 
selective agonist for peroxisome proliferator-activated 
receptor-gamma (PPARγ). PPARγ receptors are found 
in tissues important for insulin action such as adipose 
tissue, skeletal muscle and liver8. Its t1/2 is 3-7 hours. It is 
extensively bound to plasma protein (>99%), principally to 
serum albumin. It undergoes extensive hepatic metabolism 
by hydroxylation of aliphatic methylene groups. Oral dose 
of drug is excreted into the bile either unchanged or as 
metabolites and eliminated in the feces9. Thus, the aim of 
present research work is to design, development and in 




Pioglitazone was generously gifted by Panacia Biotec, Baddi 
(H.P.) India. Eudragit, Polyethylene glycol 300 and HPMC 
K4M were purchased from Central Drug House, New Delhi. 
All other chemicals used were of analytical grade.
Methods
Pioglitazone loaded mucoadhesive buccal patches were 
prepared by solvent casting technique. The weighed 
and measured quantities of Eudragit RS 100 (controlled 
release polymer) and Hydroxy propyl methyl cellulose 
K4M (mucoadhesive polymer) were dissolved in solvent 
system i.e. ethanol and the mixture were stirred until they 
were completely dissolved. Pioglitazone was separately 
dissolved in ethanol and added to polymeric solution. Later 
on, polyethylene glycol 300 (plasticizer) was added in the 
drug polymer mixture. The mixtures were prepared with a 
magnetic stirrer and cast into a petridish of 10 cm diameter 
and allowed to dry overnight at room temperature. The 
films were accurately observed and checked for possible 
imperfections upon their removal from the petridish10. The 











F1 5 5 0.5 20
F2 10 5 0.5 20
F3 15 5 0.5 20
F4 10 2.5 0.5 20
F5 10 7.5 0.5 20
FC: Formulation code
Evaluation of mucoadhesive buccal patches
Thickness uniformity: The thickness of each patch was 
measured using a micrometer screw gauge at different 
positions of the patch and the average was calculated.
Uniformity of weight: Patch was cut into 1×1 cm2. Weight 
of each patch was taken and the weight variation of a batch 
of ten patches was averaged.
Surface pH: The surface pH of patches was ascertained so 
as to investigate/ examine the possible side effects due 
to change in pH in vivo, since an acidic or basic pH may 
cause irritation to buccal mucosa. Buccal patches were left 
to swell for 2 h on the surface of the agar plate, prepared by 
dissolving 2% (w/v) agar in warmed isotonic phosphate 
buffer of pH 6.8. The surface pH was measured by means 
of electrode of pH meter placed on the surface of the 
swollen patch11.
Folding endurance: The folding endurance was computed 
by repeatedly folding one patch at the same place till 
it broke or folded up to 300 times, which is considered 
satisfactory to show good patch properties. The number of 
times of patch could be folded at the same place without 
25-31.
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breaking/cracking gave the value of folding endurance12. 
Drug content uniformity: A patch of size 1×1 cm2 was 
cut and placed in a beaker. Ten ml of a phosphate buffer 
(pH 6.8) solution was added. The contents were stirred in 
ultrasonic cleaner to dissolve the patch and filtered. The 
contents were transferred to a volumetric flask (10 ml). 
The absorbance of the solution was measured against the 
corresponding blank solution at 269 nm13.
Swelling index: The patches were allowed to swell on 
the surface of the agar plate (2% w/v agar in simulated 
salivary fluid of pH 6.8). Measurement of the weight of the 
swollen patch was done using digital weighing balance at 
hourly intervals for 4 h. The swelling was calculated from 
the following equation:
                   S (%) = [(Wt – W0)/ W0] × 100
Where, S (%) is the percent change in swelling of patches, 
Wt is the weight of the swollen patches after time t; W0 is 
the weight of patch at time zero14.
Mucoadhesive strength: Mucoadhesion is essential 
parameter for buccal drug delivery systems since it 
can increase the residence time of drug in the body. 
Modified Pan Balance technique was used to determine 
the mucoadhesive strength. An alantoine membrane (i.e. 
mucosal surface) obtained from an egg was covered the 
bottom portion of a small beaker and placed inverted in a 
large beaker containing phosphate buffer (pH 6.8), kept at 
37±1°C. The patch was placed on the alantoine membrane. 
Then, the left side pan was placed at the patch attached to 
membrane. The weights were added slowly in increasing 
order to the right pan till the patch separates from the 
alantoine membrane. The weights required for complete 
detachment of the patch from mucosal surface was noted. 
Average of three determinations was calculated15.
Ex vivo mucoadhesion time: It was carried out by applying 
patch on freshly cut porcine buccal mucosa. The mucosa 
was fixed on the internal bottom side of beaker with help 
of starch mucilage. The patch was wetted with 50 ml of 
simulated saliva fluid and was pasted to mucosa by 
applying light force by hand. The beaker was filled with 100 
ml SSF and kept at 37°C. After 2 m, a 50 rpm stirring rate 
was applied to simulate the buccal cavity. The time taken 
for patch to completely erode or detach from mucosa was 
observed as ex vivo mucoadhesion time. Dissolution media 
was continuously stirred using teflon coated magnetic 
bead to maintain sink conditions16.
In vitro drug release studies: The in vitro release of 
Pioglitazone was studied in simulated salivary fluid 
(SSF) (pH 6.8) as dissolution media using sigma dialysis 
membrane as diffusion membrane. The membrane was 
tied to one open end of double ended tube which acts 
as donor compartment. A patch of 1×1 cm2 sizes was 
cut and attached to the membrane. The assembly was 
placed in beaker contained 500 ml of SSF. 5 ml sample 
was withdrawn at intervals of 0, 15, 30, 60, 120, 240, 
360, 480, 600, 720, 960, 1200 and 1440 min and replaced 
simultaneously with fresh fluid. The collected samples 
were analyse with the help of UV spectrophotometer at 269 
nm. Finally, the cumulative amount of drug release from 
the formulation was calculated with the help of calibration 
curve of Pioglitazone to determine the release pattern. All 
measurements were carried out in triplicate and average 
values plotted. 
Release kinetic study: In order to understand the mechanism 
and kinetics of drug release, the drug release data of in 
vitro dissolution study was analyzed with various kinetic 
models like zero-order, first order, Higuchi and Korsmeyer-
Peppas model. Regression (R2) values were calculated for 
the linear curves obtained by regression analysis17. 
RESULTS AND DISCUSSION
Preparation of Patches: Preparation of Pioglitazone loaded 
mucoadhesive buccal patches was done by using Eudragit 
RS100 as sustained release and film forming polymer and 
HPMC K4M as mucoadhesive polymer with polyethylene 
glycol 300 as plasticizer. Ethanol was used as solvent to 
keep both polymers in solution. The solvent casting method 
was used to prepare buccal patches. The formulation F1, 
F2 and F3 was formulated by varying the concentration of 
Eudragit and formulation F4, F5 formulated by varying 
the concentration of HPMC K4M. Patches with higher 
concentration of Eudragit or HPMC could not be prepared 
since they could not be removed easily from the petridish 
in which they were cast and tended to fragment. Different 
formulations of pioglitazone loaded buccal patches are 
shown in Figure 1.
Thickness uniformity: The thickness of each patch was 
measured using screw gauge at different positions of 
the patch and the average was calculated. The thickness 
of patches for F1, F2, F3, F4 and F5 formulations were 
found to be 0.26±0.02, 0.27±0.45, 0.30±1.10, 0.29±0.98 and 
0.30±0.63 mm respectively. All the patches have uniform 
Figure 1. Different formulations of Pioglitazone loaded 
buccal patch.
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Evaluation Parameters F1 F2 F3 F4 F5
Thickness (mm)a 0.26±0.02 0.27±0.45 0.30±1.10 0.29±0.98 0.30±0.63
Uniformity of weight (mg)a 30.46±1.75 40.81±0.66 50.27±1.68 50.69±1.29 60.23±1.92
Surface pH 6.7 6.5 6.6 6.2 6.0
Folding endurance >300 >300 >300 250 180
Drug content uniformity (%)a 85.04±0.54 98.58±2.05 92.64±1.14 90.35±0.91 96.07±0.84
Swelling index (%)a 135±0.63 131±0.79 110±0.94 66.66±1.12 75±2.16
Mucoadhesive strengtha 21.77±0.26 38.20±1.75 31.57±1.47 23.95±2.22 37.13±0.98
Ex vivo mucoadhesion time (h) a 2±0.56 4±1.26 4.5±0.45 2±0.36 6±0.87
Cumulative In vitro drug release (%)a 69.91±0.99 95.18±1.98 89.04±2.27 80.74±0.45 85.32±2.25
Table 2. Evaluation Parameters of Pioglitazone loaded Mucoadesive Buccal Patches.
Figure 2. Cumulative In vitro Drug Release for All 
Formulations.
a Each value indicate the mean ± SD (n=3)
thickness throughout. Average thickness was found 0.284 
mm. The thickness of patches was increased on increasing 
the polymer concentration18.
Uniformity of weight: The uniformity of weight of the 
patches for F1, F2, F3, F4, and F5 formulations were 
found 30.46±1.75, 40.81±0.66, 50.27±1.68, 50.69±1.29 and 
60.23±1.92 mg respectively. 
Surface pH: The surface pH of buccal patches containing 
pioglitazone was found in the range 6.0 to 6.7. The surface 
pH of all formulations was within range of salivary pH and 
hence no mucosal irritation was expected and ultimately 
achieves patient compliance. The average of three 
determinations for each formulation is shown in Table 2.
Folding Endurance: Folding endurance was considered 
adequate to reveal good patch properties. The patches 
show folding endurance values in between 180 and >300. 
The formulations F1, F2, F3 patches did not show any cracks 
even after folding for more than 300 times. Hence it was 
taken as the end point. The patches were found uniform. 
But the F5, F6 formulations shows 150 and 80 times folding 
of patches which means patches were not uniform. The 
folding endurance of the patches decreases with increase 
in polymer concentration. The folding endurance of the 
patches is more than 300 which show the patches are 
having high mechanical strength and good elasticity19. F5 
showed minimum folding endurance. However, all the 
patches showed satisfactory flexibility.
Drug content uniformity: Drug content uniformity of 
formulation F1 to F5 varied from 85.04±0.54 to 98.58±2.05%. 
The results of drug content uniformity from table 2 
indicated that the drug was uniformly dispersed. The drug 
content of all the patches was found to be uniform with low 
SD values, which indicates that the drug was distributed 
uniformly in all the patches. 
Swelling Index: The swelling index of formulations F1, F2, 
F3, F4 and F5 was found to be 135±0.63, 131±0.79, 110±0.94, 
66.66±1.12 and 75±2.16% respectively after 4 h. The Eudragit 
contained buccal patches showed highest swelling index13. 
Mucoadhesive strength: As the amount of mucoadhesive 
polymer (HPMC K4M) increases the mucoadhesion 
was found to be increase. Peak detachment force is the 
maximum applied force at which the patch detaches from 
tissue. The mucoadhesive strength for formulation F1, 
F2, F3, F4 and F5 was found to be 21.77±0.26, 38.20±1.75, 
31.57±1.47, 23.95±2.22 and 37.13±0.98 respectively. 
Ex vivo mucoadhesion time: The patches composed of 
larger amounts of the mucoadhesive polymer, HPMC 
showed the greatest mucoadhesion time of nearly 6 h 
indicating their suitability for use in buccal drug delivery. 
Comparatively shorter mucoadhesion time was observed 
with patches containing higher amounts of the retardant 
polymers. 
In vitro drug release studies: The in vitro drug release of 
formulations F1, F2, F3, F4 and F5 was found to be 69.91±0.99, 
95.18±1.98, 89.04±2.27, 80.74±0.45 and 85.32±2.25% in 24 
h (i.e. 1440 min) respectively.  At pH 6.8, Eudragit RS100 
retarded the release rate of drug from HPMC patches. 
An increase in the polymer content was associated with a 
corresponding decrease in the drug-release rate5. The data 
for cumulative in vitro drug release for all formulations are 
given in Table 3 and illustrates in Figure 2. 
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Table 3. Data for Cumulative In vitro drug release for all Formulations.
Release kinetic study: The kinetics and mechanism of 
drug release was determined using zero order, first order, 
Higuchi’s square root equation and further analysis 
was performed using Korsemeyer-Peppas equation. 
All formulations were found to be followed Higuchi’s 
square root equation as the plot showed high linearity 
(R2= 0.956 to 0.984) as shown in Table 4. This equation 
indicates that the amount of drug release is proportional 
to the square root of time for the diffusional release of a 
drug from the formulation. The calculated ‘n’ values from 
power law equation (Korsemeyer- Peppas equation) for 
drug release profiles were between 0.745-0.782, suggest 
that drug release mechanism from formulations followed 
Non-Fickian (anomalous) transport mechanism, which 
indicates that the drug release rate is controlled by coupled 
diffusion and erosion20. The in vitro release kinetics data for 
all formulations are given in Table 4. 
CONCLUSION
A novel mucoadesive buccal patch of Pioglitazone was 
successfully fabricated via solvent casting technique 
using HPMC K4M as mucoadhesive polymer and 
Eudragit RS100 as controlled release polymer. Prepared 
patches have shown higher mucoadhesive strength with 
sustained release characteristics. The observed data for 
all physical and in vitro evaluation parameters illustrates 
F2 as optimized formulation among all. Thus, it can be 
concluded that the current research on pioglitazone loaded 
mucoadesive buccal patches can prove to be promising 
dosage form for the active ingredient in comparison with 
conventional dosage forms. 
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